Biofidelity

Biofidelity is a rapidly growing commercial-stage genomic technology company founded in 2019 and based in the United Kingdom. The company's slogan, "Transforming human health by developing innovative technologies that unleash the potential of genomics," reflects its dedication to bringing the benefits of precision medicine to patients worldwide. Their first product, ASPYRE-Lung, has been launched in the US, and they boast an extensive pipeline of novel products. Biofidelity has developed a novel molecular biology technology that enables genomic analysis for cancer diagnosis to be carried out locally, quickly, and far more cost-effectively. This innovation holds the potential to significantly impact the field of biotechnology and healthcare. Notably, Biofidelity secured a $24.00M Venture Round investment on 03 April 2024, with participation from prominent investors including Blue Yard Capital, Octopus Ventures, Longwall Ventures, and Agilent Technologies. This significant investment attests to the confidence and support the company has garnered within the industry.